• James Healy, MD, PhD

  • General Partner, Sofinnova Ventures

  • Jim has over 20 years of experience in bio-medical research, development, and finance. He joined Sofinnova in 2000 as a General Partner, and specializes in funding private and publicly traded bio-pharmaceutical companies. Jim has financed and served on the board of ten companies which received drug approvals from either the FDA or EMA. He was an early investor and board member of thirteen companies which subsequently completed initial public offerings and ten companies that have been acquired as private or public companies. He invests throughout the US and Europe.

    Previous investments and board memberships include Anthera (ANTH), Cellective (acquired by AstraZeneca), CoTherix (CTRX, acquired by Actelion), Durata (DRTX, acquired by Actavis), InterMune (ITMN, acquired by Roche), Kalobios (KBIO), Movetis (MOVE, acquired by Shire), NextWave (acquired by Pfizer), Novacea (NOVC, merged with Transcept), Preglem (acquired by Gideon Richter), Prestwick (acquired by Biovail), and Salveo (acquired by Catamaran).

    Jim presently serves on a board of directors of Amarin (AMRN), Auris (EARS), Coherus (CHRS), Edge (EDGE), and is the Chairman of the Board at Hyperion (HPTX). He also serves on the board of directos of Ascendis, NuCana, and other private companies.

    In 2011, Jim won the IBF Risk Master Innovator Award and was named as one of the industry's top life science investors in 2013 by Forbes Magazine. Jim is a Director on the Board of the National Venture Capital Association (NVCA) and has been appointed to the Emerging Companies Section Governing Board of the Biotechnology Industry Organization (BIO).

    Previously, Jim served as a member of the Executive Board of the College of Letters and Science at the University of California at Berkeley and has lectured on entrepreneurship at Stanford University. Prior to Sofinnova, Jim worked at Bayer (Miles), Sanderling, and consulted at ISTA Pharmaceuticals.

  • James-Healy.jpg